Join Amanda Mixon, PA-C, President of RhAPP, as she hosts an insightful discussion with Will Saalfeld, NP, a leading rheumatology expert and RhAPP faculty member. In this episode, they break down the key differences between IL-17A and IL-17F inhibition and explore how these distinctions impact patient outcomes in rheumatology.

IL-17A and IL-17F play central roles in inflammation and autoimmune disease, but their unique functions mean that blocking them can yield different clinical effects. Will explains the pathophysiology of these cytokines, their impact on diseases like psoriatic arthritis and axial spondyloarthritis, and how emerging therapies are targeting both IL-17A and IL-17F for broader disease control.

They also dive into real-world applications, including the latest clinical trials and how IL-17 inhibitors compare in efficacy, safety, and patient selection. Learn why dual inhibition of IL-17A and IL-17F may offer additional benefits over targeting IL-17A alone and what considerations are essential when prescribing these biologics.

For more expert-driven rheumatology content, visit RhAPP.org and explore the RhAPP ACE App for the latest updates, research, and clinical insights.